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Venomous mammals are rare (1) , and their venoms have not been characterized. Toxic constituents produced by vertebrates, such as snake, scorpion, lizard, and frog, have been well studied. Several bird species (the genus Pitohui) are also known to contain steroidal alkaloid toxin as a chemical defence (2) . However, only a few members of the order Insectivora produce toxic compounds, including the Haitian solenodon (Solenodon paradoxus), the European water shrew (Neomys fodiens), the Mediterranean shrew (N.
anomalous), and the American short-tailed shrew (Blarina brevicauda) (3) (4) (5) (6) . Mammals in other orders, Monotremata (platypuses and echidnas), are also suspected to have venom (7) .
Envenoming by Platypus causes immediate excruciating pain that evolves toward prolonged hyperalgesia. Defensin-like peptides (8) and the C-type natriuretic peptides (9) have been isolated from this venom. However, the precise mechanism of the excruciating pain caused by platypus toxin in humans remain unclear.
Among mammals, the short-tailed shrew B. brevicauda (Say, 1923 ) is well known to produce a potent venom in its saliva, which is toxic to mammals, such as mice, voles, rabbits and cats (1, 3) . Human accounts of bites from Blarina describe a local burning sensation around the tooth puncture marks and subsequent swelling (10) . In general, Soricine shrews consume large amounts of food to meet their high metabolic demands (11) .
Although they belong to the order "Insectivora", B. brevicauda do not eat insects and invertebrates exclusively, but also vertebrates, even larger than themselves, such as murid rodents and frogs (1, (11) (12) (13) . Therefore, this shrew species may use its venom to paralyze and catch larger preys.
The stability of crude extracts of Blarina submaxillary glands has been studied (14, 15) .
Its toxicity was lost rapidly at pH >7 and gradually at room temperature. Products from precipitation of the crude extracts with ammonium sulfate (33-80% saturation) are toxic.
Therefore, it has been suggested that the most toxic ingredient is a high molecular weight 5 watersoluble protein, not a carbohydrate or nucleoprotein (1) . However, since the Blarina venom loses its toxicity rapidly after death, its purification and more precise identification have not been successfully completed.
In the present study, we purify and characterize the B. brevicauda venom, blarina toxin (BLTX). This venom exerted a kallikrein-like proteolytic activity similar to that of a lizard venom (16) . were excised immediately after the animals were trapped, and stored in acetone at -20°C as described (3) . Tissues were also immediately stored in RNAlater for mRNA extraction, according to the manufacturer's instructions. All animals were treated in accordance with the ethical guidelines of the International Association for the Study of Pain (17) .
Materials and Methods

Chemicals
Purification of Venom.
All procedures were performed at 4-6 °C and all separation systems and columns were purchased from Amersham Biosciences Inc. Fifteen submaxillary and sublingual glands specimens were homogenized with 0.85% NaCl and nm and 460 nm, respectively, at 37 °C, as previously described (18) . For inhibition studies, BLTX was preincubated with various inhibitors for 5 min at 37 °C before measurements of activity.
The conversion of kininogens to small peptides was measured by incubating 0.2 mg ml -1 LK and HK in 50 mM Tris-HCl buffer, pH 9.0, with purified BLTX or PPK (14 ng) at 37 °C, with a reaction mixture volume of 20 µl. At 0, 10, 30, and 60 min, 5 µl of the reaction mixture was withdrawn and added to 5 µl of denaturing solution, as previously described (16) . The samples were boiled for 5 min, SDS-PAGE was performed using a precast 10% polyacrylamide gel, and the gels were stained with a Silver Stain Kit, Protein.
For the HPLC analysis of degradation products, LK and HK (10 µg) were incubated as described above, except for a concentration of BLTX of 0.4 µg in 50 µl of reaction mixture.
The mixture was boiled for 10 min, diluted with 150 µl of 0.1 M ammonium acetate and ultrafiltered through a Microcon YM-10 (cut-off M r , 10,000; Millipore Co.). After lyophilization of 180 µl of filtrate, the degradation products were loaded on a Develosil RP-AQEUOUS AR-5 column and eluted with 18% acetonitrile containing 0.1% trifluoroacetic acid, at a flow rate of 120-130 µl min -1 , with monitoring at 215 nm.
Measurement of Vascular Tone.
Fresh bovine hearts were obtained from a local slaughterhouse. The coronary arteries were dissected free of connective tissue and cut into 3-to 4-mm long ring segments and suspended in a tissue bath containing a Krebs-Ringer bicarbonate buffer at 35 °C and bubbled with a mixture of 95% O 2 and 5% CO 2 . Isometric tension was measured as previously described (19) . Briefly, arterial rings were slowly attached to a basal tension of 1.5 g. After equilibration, KCl (60 mM) was repeatedly added and rinsed until stable and reproducible contractions were observed. The thromboxane mimetic, U46619 (500 nM), was added to increase the tension to ~50% -75% of maximal First-strand cDNA template was prepared from 1 µg of total RNA using ImProm-II Reverse
Transcriptase in the presence of an Oligo-dT primer. After cDNA synthesis, polymerase chain reaction (PCR) was carried out using the degenerate oligonucleotides, KLK-His and KLK-Ser, designed from the conserved amino acid sequences within the active sites of mammal kallikreins. All the primer sequences, including gene-specific primers, KLK-1~5, are shown in Table 1 . The PCR conditions were as follows: an initial denaturing at 95 °C for 5 min, followed by 33 cycles of 30 sec of denaturing at 95 °C, 30 sec of annealing at 60 °C, and 30 sec of extension at 72 °C, and a final extension at 72 °C for 7 min. Amplified products were subcloned into pGEM-T Easy vector (Promega) and sequenced using dye terminator reactions with an automated ABI PRISM 3100 Avant Genetic Analyzer (PE Applied Biosystems). The 22 independent clones were sequenced, three of which were completely matched with the sequences corresponding to the amino acid sequences within BLTX. Two other novel tissue kallikrein isoforms were obtained from the other clones.
Based on the deduced nucleotide sequence of PCR fragment, 3'-rapid amplification of cDNA ends (RACE) was carried out with KLK-1 and the Oligo-dT primer. Hemi-nested PCR was performed using KLK-2 and the Oligo-dT primer. For the 5'-RACE reaction, first-strand cDNA template was synthesized using a SMART RACE cDNA Amplification Kit (BD Bioscience) according to the manufacturer's instructions and PCR was performed using a universal primer mix (long;
5'-CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3', short;
5'-CTAATACGACTCACTATAGGGC-3') and KLK-3.
The full-length BLTX cDNA was confirmed by PCR, using KLK-4 and KLK-5. The PCR conditions were as follows: an initial denaturing at 94 °C for 3 min, followed by 30 cycles of 30 sec of denaturing at 94 °C and 90 sec of annealing and extension at 68 °C, and a final extension at 72 °C for 7 min. The amplified DNA fragments were subcloned and 10 independent clones were sequenced. All clones showed an identical sequence.
Results
Purification of the BLTX. Instead of saliva, we used extracts from 500 mg of B.
brevicauda submaxillary and sublingual glands as starting material, and purified them through a series of standard chromatographic procedures. The toxicity coincided with a 11 protein peak on analytical gel permeation and anion-exchange HPLC (Fig. 1, A-C M), the Kunitz-type soybean trypsin inhibitor (KSTI), and leupeptin, and was not inhibited by urinary trypsin inhibitor (UTI) or  1 -protease inhibitor ( 1 PI) ( Table 2 ).
On SDS-PAGE analyses, BLTX converted human LK and HK into various peptides in a time-dependent manner (Fig. 4, A-B) . PPK was used as a positive control, and the HK and LK degradation products resulting from incubation with BLTX and PPK appeared identical.
Aprotinin, in a concentration of 10 µM, markedly suppressed the degradation of kininogens by BLTX. HPLC analysis of the degradation products revealed the release of bradykinin 13 (BK), lysyl-BK and methionyl-lysyl-BK from LK (in approximately 1:2:1 ratios), and mostly BK from HK (Fig. 4, C-F) . The various amino acid sequences were determined by MS-MS analysis. These products were identical to those formed by human tissue kallikrein, suggesting that BLTX exerts a tissue kallikrein-like activity. Furthermore, a prominent vasodilation by LK treated with BLTX was observed in the measurement of tension on the bovine coronary artery preconstricted by U46619. This vasodilation was equivalent to that produced by BK (Fig. 4, G 
-H).
To determine the relationship between the lethal and proteolytic activities of BLTX, we analyzed the effects of protease inhibitors on its acute toxicity ( Table 3) . Treatment of the crude extracts of Blarina salivary glands with aprotinin and leupeptin in maximal concentrations of 7.8 and 240 µM, respectively, completely abolished its acute toxicity, such that all treated animals survived. While the administration of these inhibitors in concentrations equivalent to 50% of maximum did not completely suppress the lethal effects of BLTX, the time to death after its administration was significantly lengthened.
Treatment of crude toxin with a plasma kallikrein inhibitor (23) and EDTA, in concentrations of 1 and 10 mM respectively, did not suppress its lethal properties. The lethality of purified BLTX was also inhibited by treatment with 7.8 µM aprotinin.
Discussion
Our study shows that the shrew Blarina, one of the smallest and most primitive mammals, produces BLTX, a multifunctional tissue kallikrein-like protease in saliva. BLTX human plasmin (24, 25) , human plasma kallikrein (huPK) (26) , and human thrombin (27) ( Fig. 5) . BLTX has highly conserved flanking residues at a catalytic triad, and 10 highly conserved cysteine residues that may form disulfide bonds and stabilize the catalytic pocket.
It has a characteristic motif (residues 97-115) containing a unique insertion of 10 residues, The enzymatic properties of BLTX, i.e., optimum pH, substrate and inhibitor specificities, and kininogen cleavage activity were similar to those of tissue kallikreins.
Although the potent inhibitory effect of aprotinin on the proteolytic activity of BLTX was similar to that exerted on tissue kallikrein, the efficiencies of other inhibitors, such as KSTI and  1 PI, were different from those of tissue kallikrein (28) . In addition, a specific inhibitor of plasma kallikrein, had no effect on the toxicity of BLTX. These observations indicate that BLTX is a tissue kallikrein family protein with its own unique properties.
Several serine proteases have been identified in reptilian venom. Snake venom is often referred to as a thrombin-like enzyme, because of its fibrinolytic activity and interference with blood coagulation (29) (30) (31) . However, the factors contributing to the lethality of snake venom are relatively small proteolytic degradation products with molecular sizes of 60-75 amino acids. Among lizard venoms, GTX and horridum toxin resemble mammal kallikreins with regard to their amino acid sequences and protease activities (16, (32) (33) (34) . BLTX readily cleaved both LK and HK, and produced kinins including BK. BK is a mediator of inflammation which increases vascular permeability, lowers blood pressure, raises the pain threshold, stimulates cell growth and differentiation (35, 36) , and is degraded by kininase in vivo. Therefore, kinins produced by BLTX may be one of the main toxic pathogens, explaining some of the manifestations observed in mice after its injection, such as dyspnea, hypotension and hypokinesia. In addition, tissue kallikreins degrade not only kininogens but also various proteins in vivo, including growth factors, hormones and extracellular matrix, and produce bioactive compounds involved in apoptosis, angiogenesis and tumor metastasis (37) . These observations also suggest that proteolytic activity of BLTX is the source of one or more unknown toxic product(s) as well as of BK and related compounds. Residual activity was calculated as a percentage of that of the enzyme without inhibitor. 
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